This fact was exploited for the development of the first IL13Rα2-specific CAR, which included a so-called zetakine composed of an extracellular altered IL13 domain and demonstrated effective tumor cell lysis in human xenograft models [99]. Here, IL13RA2 is linked to neoplasm.